Ricardo Suruagy-Motta

💡Medical Student & Researcher in Cardiology 🫀

[Ricardo Suruagy-Motta @ricosuruagy]

@evandrofilhobr 👏🏼✅

[Evandro Martins F. MD @evandrofilhobr]

When a chronically protruding LM stent precludes selective coronary engagement, TAVR planning gets complicated.
Our approach: intentional percutaneous stentectomy followed by DCB-only angioplasty, leaving a completely metal-free ostium for future coronary access.
TAVR was performed successfully.
Published in CRM: Interesting Cases
@ricosuruagy
https://t.co/oCAorNnMSe

[Evandro Martins F. MD @evandrofilhobr]

Despite increasing use in complex PCI, rotational atherectomy through guide extension catheters has never been comprehensively reviewed.

Available now at Journal of Interventional Cardiology, our new open-access review summarizes the evidence, technical principles, indications, limitations, and practical tips for this niche but valuable technique.

Hope you find it useful.

https://t.co/UEqQzMGxri

@tomkaier @DrBIqbal @pmachado_gui @realarainmd @ricosuruagy @GEICC3 @marielle2l

#InterventionalCardiology #Rotablator #ComplexPCI #OpenAccess

[Ricardo Suruagy-Motta @ricosuruagy]

@evandrofilhobr 👏🏼👏🏼👏🏼

[Ricardo Suruagy-Motta @ricosuruagy]

@evandrofilhobr Honored to contribute to this discussion! Our findings suggest that while 'shorter is better' works for many, bifurcation lesions remain a high-risk outlier. Proud of the team’s work🫀

[Evandro Martins F. MD @evandrofilhobr]

Pleased to share our new publication in Coronary Artery Disease.

In patients undergoing PCI for coronary bifurcation lesions, short DAPT (≤6 months) was associated with higher risks of MACE, death, and stent thrombosis.

In bifurcation PCI, anatomy matters. So does DAPT duration.

Still remains a key unanswered question: how DAPT duration should interact with PCI optimization by IVUS/OCT, bifurcation complexity, and 1-stent vs 2-stent strategies?

Kudos to @ricosuruagy

https://t.co/KdqpQF0Cya

#PCI #BifurcationPCI #DAPT #InterventionalCardiology #CardioTwitter #CardioX

[Ricardo Suruagy-Motta @ricosuruagy]

Tribuna Hoje - Estudante de Medicina do Cesmac publica artigo em revista internacional em parceria com pesquisadores de Harvard https://t.co/f6pDUbj3Ap

[Ricardo Suruagy-Motta @ricosuruagy]

@evandrofilhobr Incredible! Very nice resume of a such important trial 👍🏼👏🏼

[Evandro Martins F. MD @evandrofilhobr]

1/16 🧵 ORBITA-CTO: The first randomized, placebo-controlled trial of CTO PCI.

📰 Published in JACC, presented at #ACC26.

🔬 Finally, sham-controlled evidence for what we do in the cath lab every day.

One of the best designed studies I have ever seen!

A biostatistical deep dive. Let's go. 👇

[Evandro Martins F. MD @evandrofilhobr]

🫀 Limus vs. Paclitaxel DCB for In-Stent Restenosis, meta-analysis of 6 RCTs (1,038 pts) in AJC 2026:

➡️ PCB reduced TLR vs LCB (RR 1.48; p=0.04) ➡️ Mortality, MI, MACE, stent thrombosis: no difference ➡️ Angiographic outcomes: equivalent
Modest advantage of paclitaxel in preventing restenosis, without impacting hard clinical endpoints.
🔗 https://t.co/rqLxNTOlBK

[Evandro Martins F. MD @evandrofilhobr]

Rotational/orbital atherectomy vs intravascular lithotripsy?

ROLLING STONE (JACC Intv 2026):
✔️ Similar procedural success
✔️ Lower early and late MACE with IVL after adjustment

“Controlled” plaque modification.

https://t.co/YkQUPzYnyE

[Carlos Collet MD PhD @ColletCarlos]

🚀 A major milestone for the CT-guided PCI 🚀

We are thrilled with the enrollment of the first patient in the "P5" OPTIMAL randomized clinical trial 💪

This is the second large RCT evaluating the value of CT-guided PCI. This time, in patients with severe coronary calcification

👏 Congratulations to Dr. @foroic and the team at Hospital de León 🇪🇸 for successfully enrolling the first patient in Spain!

We now look forward to the start of recruitment across:🇧🇪 |🇩🇰 | 🇬🇧 | 🇺🇸

@TCTMD @crfheart @fundacionepic @jcspratt @esbrilakis @yadersandoval @BartsIntervGrp @PCRonline @Heartflow @ShockwaveIVL

[Carlos Collet MD PhD @ColletCarlos]

We’re moving at an unprecedented pace in understanding atherosclerosis.

The real breakthrough will come from combining morphology + physiology to define lesion-level risk.

Our editorial @JACCJournals @crfheart

[Evandro Martins F. MD @evandrofilhobr]

Great learning case today.

61M, MVD, CCS I-II angina, CABG turndown (targets RCA & LCx).

After treating a complex subtotal & calcified RCA with Rota-shock, I moved to the next challenge: LCx CTO

This time I pushed myself to apply the 3D wiring principles and used the ADAPT technique to understand tip direction, depth, and true spatial alignment.
I’m still early in my journey with angiographic 3D wiring (LCx probably the most challenging for 3DW), and there is a lot I need to improve but every case is an opportunity to develop precision, mental 3D visualization, and structured wiring strategy.
Huge respect for the experts who mastered this before us.
Step by step, one case at a time.
Committed to learning and getting better.

[Ricardo Suruagy-Motta @ricosuruagy]

🔥 Hot off the Press

Our Meta-analysis compares PMA vs. Surgery for TVIE, with @GreggWStone

Key Findings:
🏥PMA reduced Hospital Stay (MD {-7.00} days)

⚠️PMA increases 30-Day Mortality (RR 2.71)

No difference in 1y mortality or readmission 🫀

[Ricardo Suruagy-Motta @ricosuruagy]

Thank you for your guidance and support throughout this process. It was a true honor to present a case regarding an interventionist as renowned as you, @evandrofilhobr . You are a great inspiration for me 👊🏼

[Evandro Martins F. MD @evandrofilhobr]

Proud of my mentee @ricosuruagy & @dias_freir19521 presenting 2 challenging cases and 4 abstracts at #TCT2025

[Ricardo Suruagy-Motta @ricosuruagy]

🔥 TCT-1007 Abstract

Long DAPT for CTO: Meta-analysis confirms the survival benefit!

💡Extended DAPT significantly reduced Mortality in CTO patients:

🫀CV Death: \log-OR -1.39 (98.7% benefit)

📉 All-cause: \log-OR -1.50

No significant difference in bleeding🩸

#TCT #DAPT

[Evandro Martins F. MD @evandrofilhobr]

💥 The #VICTORY Trial presented at #TCT2025:
In OCT-guided PCI for severely calcified coronary lesions, OPN non-compliant balloon was non-inferior to intravascular lithotripsy (IVL) for stent expansion — with fewer devices, shorter procedures, and lower cost.

#TCT2025 #Cardiology #IVL #CalcifiedLesions

[Ricardo Suruagy-Motta @ricosuruagy]

@evandrofilhobr Congratulations!

[Gregg W. Stone MD @GreggWStone]

Our study on outcomes of OCT/IVUS vs. angio guidance of DES in 2005 severely calcified lsns in ECLIPSE publ in JACC CV Int. Img used in 62% (dr discretion) associated with 26% adj decr in TVF. Consistent w/orbital atherectomy or balloon vessel prep. Link https://t.co/x00yLj7JO2